28 products were found matching "K19261"!
No results were found for the filter!
respiratory syncytial virus B Fusion glycoprotein F0 (F),...
Item number: CSB-YP516611HXK.1
Organism: Human respiratory syncytial virus B (strain B1). Source: Yeast. Expression Region: 137-574aa. Protein Length: Partial. Tag Info: N-terminal 6xHis-tagged. Target Protein Sequence: FLGFLLGVGS AIASGIAVSK VLHLEGEVNK IKNALLSTNK AVVSLSNGVS VLTSKVLDLK NYINNQLLPI VNQQSCRISN IETVIEFQQK NSRLLEINRE FSVNAGVTTP...
| Keywords: | F, Recombinant Human respiRatory syncytial virus B Fusion glycoprotein F0 (F), partial |
| Application: | Activity not tested |
| Expressed in: | Yeast |
| Origin: | Human respiratory syncytial virus B |
| MW: | 50.1 kD |
From 242.00€
*
Sisunatovir
Item number: TGM-T24747-2mg
Description: RV521 is a highly effective fusion inhibitor. It designed to treat RSV disease by the target of a surface protein that mediates RSV binding to cellular receptors. Target: Others. Smiles: NCc1ccc2n(CCCC(F)(F)F)c(CN3C(=O)C4(CC4)c4ccc(F)cc34)nc2c1
| Keywords: | RV521, RV-521, RV 521, RV521 free base |
| Application: | Targets Pneumoviridae fusion glycoprotein F0 (F) |
| CAS | 1903763-82-5 |
| MW: | 446.44 D |
From 83.00€
*
Clesrovimab
Item number: TGM-T77132-10mg
Description: Clesrovimab (MK1654) is an anti-respiratory syncytial virus protein F human monoclonal antibody for the prevention and treatment of respiratory syncytial virus infections. Target: Others. References: Qiu X, et al. Development of mRNA vaccines against respiratory syncytial virus (RSV). Cytokine Growth...
| Keywords: | MK-1654 |
| Application: | Targets Pneumoviridae fusion glycoprotein F0 (F) |
| CAS | 2429913-18-6 |
From 430.00€
*
Palivizumab
Item number: TGM-T76907-100mg
Description: Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV). Target: RSV. References: Palivizumab, a humanized respiratory syncytial...
| Keywords: | MEDI 493, Synagis |
| Application: | Targets Pneumoviridae fusion glycoprotein F0 (F) |
| CAS | 188039-54-5 |
From 215.00€
*
Sisunatovir hydrochloride
Item number: TGM-T9197-100mg
Description: Sisunatovir hydrochloride (RV521 HCl) is an orally available inhibitor of the RSV-F protein that has exhibited potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses in vitro (IC50 = 1.4 nM for RSV-A, IC50 = 1.0 nM for RSV-B). Target: RSV. Smiles:...
| Keywords: | Sisunatovir HCl, RV521 HCl |
| Application: | Targets Pneumoviridae fusion glycoprotein F0 (F) |
| CAS | 1903763-83-6 |
| MW: | 482.9 D |
From 49.00€
*
Presatovir
Item number: TGM-TQ0085-100mg
Description: Presatovir (GS-5806) (GS-5806) is a novel, orally bioavailable RSV fusion inhibitor (mean EC50: 0.43 nM). Target: RSV. Smiles: Cc1cn2nc(cc2nc1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(C)(=O)=O. References: Samuel D, et al. GS-5806 inhibits pre- to postfusion conformational changes of the...
| Keywords: | GS-5806 |
| Application: | Targets Pneumoviridae fusion glycoprotein F0 (F) |
| CAS | 1353625-73-6 |
| MW: | 532.06 D |
From 55.00€
*
Sisunatovir
Item number: Cay42124-10
An RSV fusion inhibitor (IC50 = 0.9 nM), reduces RSV A2 replication in a plaque reduction assay in vitro (EC50 = 1.3 nM), decreases lung viral titers in a mouse model of RSV infection at 1, 10, or 50 mg/kg. Formulation: A solid. InChI:...
| Keywords: | RV521,... |
| Application: | RSV fusion inhibitor |
| CAS | 1903763-82-5 |
| MW: | 446.44 D |
From 169.00€
*
Nirsevimab (YTE Mutant)
Item number: BPS-83759-1
Nirsevimab, also known as MEDI8897, is a recombinant neutralizing monoclonal antibody developed against human respiratory syncytial virus (RSV). It is an IgG1kappa antibody, that has a triple mutation in the Fc region designed to increase its serum half-life. The YTE (M252Y/S254T/T256E) mutation increases the...
| Keywords: | F, Fusion glycoprotein F0 |
| Application: | Biochemical, cellular assays |
| Host: | Hamster |
| Species reactivity: | human |
| CAS | 1989556-22-0 |
From 1,500.00€
*
Motavizumab
Item number: TGM-T76752-5mg
Description: Motavizumab (MEDI-524) is a monoclonal antibody targeting the respiratory syncytial virus (RSV). It is utilized in research focused on RSV infections in high-risk infants [1].
| Application: | Targets Pneumoviridae fusion glycoprotein F0 (F) |
| CAS | 677010-34-3 |
803.00€
*
Suptavumab
Item number: TGM-T76992-10mg
Description: Suptavumab (REGN2222) is a human monoclonal antibody that neutralizes conserved epitopes on subtypes A and B of RSV, making it useful for studying RSV infections and the respiratory system. Target: RSV. References: Simões EAF, et al. Suptavumab for the Prevention of Medically Attended Respiratory...
| Keywords: | REGN2222 |
| Application: | Targets Pneumoviridae fusion glycoprotein F0 (F) |
| CAS | 1629615-23-1 |
From 248.00€
*
Felvizumab
Item number: TGM-T77005-5mg
Description: Felvizumab (SB 209763), a humanized IgG1kappa monoclonal antibody, targets specific neutralizing epitopes on the F glycoprotein of Respiratory Syncytial Virus (RSV) [1] [2].
| Application: | Targets Pneumoviridae fusion glycoprotein F0 (F) |
| CAS | 167747-20-8 |
Please request pricing for this article.
Nirsevimab
Item number: TGM-T77100-10mg
Description: Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with a modified Fc region, efficiently targeting RSV-B with a Kd value of 1.5 nM, and can be used to prevent RSV infection. Target: RSV. References: Griffin MP, et al. Single-Dose Nirsevimab for Prevention...
| Keywords: | MEDI8897 |
| Application: | Targets Pneumoviridae fusion glycoprotein F0 (F) |
| CAS | 1989556-22-0 |
From 470.00€
*